Danaher EBITDA 2010-2024 | DHR
Danaher annual and quarterly EBITDA history from 2010 to 2024. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Danaher EBITDA for the quarter ending December 31, 2024 was $1.549B, a 9.84% decline year-over-year.
- Danaher EBITDA for the twelve months ending December 31, 2024 was $7.123B, a 0.44% increase year-over-year.
- Danaher 2023 annual EBITDA was $7.376B, a 23.71% decline from 2022.
- Danaher 2022 annual EBITDA was $9.668B, a 13.77% increase from 2021.
- Danaher 2021 annual EBITDA was $8.498B, a 31.49% increase from 2020.
| Danaher Annual EBITDA (Millions of US $) |
|
|---|---|
| 2023 | $7,376 |
| 2022 | $9,668 |
| 2021 | $8,498 |
| 2020 | $6,463 |
| 2019 | $4,458 |
| 2018 | $4,233 |
| 2017 | $3,689 |
| 2016 | $3,863 |
| 2015 | $3,043 |
| 2014 | $2,763 |
| 2013 | $3,971 |
| 2012 | $4,005 |
| 2011 | $3,252 |
| 2010 | $2,438 |
| 2009 | $1,771 |
| Danaher Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2024-09-30 | $1,549 |
| 2024-06-30 | $1,748 |
| 2024-03-31 | $1,923 |
| 2023-12-31 | $1,903 |
| 2023-09-30 | $1,718 |
| 2023-06-30 | $1,703 |
| 2023-03-31 | $2,052 |
| 2022-12-31 | $1,619 |
| 2022-09-30 | $2,555 |
| 2022-06-30 | $2,757 |
| 2022-03-31 | $2,737 |
| 2021-12-31 | $1,560 |
| 2021-09-30 | $1,880 |
| 2021-06-30 | $2,530 |
| 2021-03-31 | $2,528 |
| 2020-12-31 | $2,149 |
| 2020-09-30 | $1,800 |
| 2020-06-30 | $1,519 |
| 2020-03-31 | $995 |
| 2019-12-31 | $1,261 |
| 2019-09-30 | $1,072 |
| 2019-06-30 | $1,110 |
| 2019-03-31 | $1,016 |
| 2018-12-31 | $815 |
| 2018-09-30 | $1,152 |
| 2018-06-30 | $1,202 |
| 2018-03-31 | $1,064 |
| 2017-12-31 | $716 |
| 2017-09-30 | $1,071 |
| 2017-06-30 | $980 |
| 2017-03-31 | $923 |
| 2016-12-31 | $1,019 |
| 2016-09-30 | $976 |
| 2016-06-30 | $988 |
| 2016-03-31 | $881 |
| 2015-12-31 | $265 |
| 2015-09-30 | $616 |
| 2015-06-30 | $1,171 |
| 2015-03-31 | $991 |
| 2014-12-31 | $941 |
| 2014-09-30 | $1,071 |
| 2014-06-30 | $1,125 |
| 2014-03-31 | $1,014 |
| 2013-12-31 | $1,077 |
| 2013-09-30 | $1,038 |
| 2013-06-30 | $1,063 |
| 2013-03-31 | $948 |
| 2012-12-31 | $1,083 |
| 2012-09-30 | $966 |
| 2012-06-30 | $1,019 |
| 2012-03-31 | $937 |
| 2011-12-31 | $983 |
| 2011-09-30 | $851 |
| 2011-06-30 | $729 |
| 2011-03-31 | $689 |
| 2010-12-31 | $659 |
| 2010-09-30 | $649 |
| 2010-06-30 | $615 |
| 2010-03-31 | $515 |
| 2009-12-31 | $370 |
| 2009-09-30 | $550 |
| 2009-06-30 | $430 |
| 2009-03-31 | $421 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $150.197B | $23.875B |
| Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products. The company's segmental details are provided below: Life Sciences segment offers a broad range of research tools used to analyze a range of critical areas including genes, proteins, metabolites and cells to understand the causes of diseases, identify new therapies, and test new drugs and vaccines. Range of industries served includes biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial. Diagnostics segment offers analytical instruments, reagents, consumables, software and services that are deployed in reference laboratories, hospitals, physicians' offices and other critical care settings. It helps to diagnose diseases and take suitable treatment decisions. Environmental & Applied Solutions segment offers products and services that help keep food and water supplies safe globally. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $90.566B | 11.84 |
| CVS Health (CVS) | United States | $82.065B | 12.01 |
| Cencora (COR) | United States | $47.211B | 17.13 |
| DiDi Global (DIDIY) | China | $23.282B | 0.00 |
| Natera (NTRA) | United States | $22.205B | 0.00 |
| ICON (ICLR) | Ireland | $16.651B | 14.81 |
| BioMerieux (BMXMF) | France | $14.074B | 0.00 |
| Doximity (DOCS) | United States | $14.002B | 72.82 |
| Revvity (RVTY) | United States | $13.962B | 23.41 |
| Viatris (VTRS) | United States | $13.201B | 4.07 |
| Solventum (SOLV) | United States | $12.870B | 0.00 |
| Avantor (AVTR) | United States | $11.909B | 17.49 |
| CochLear (CHEOY) | Australia | $11.330B | 0.00 |
| Medpace Holdings (MEDP) | United States | $10.506B | 27.30 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $9.794B | 0.00 |
| HealthEquity (HQY) | United States | $9.682B | 48.57 |
| Sonic Healthcare (SKHHY) | Australia | $8.686B | 0.00 |
| Charles River Laboratories (CRL) | United States | $8.297B | 15.72 |
| Amplifon S.p.A (AMFPF) | Italy | $6.224B | 31.72 |
| Bausch + Lomb (BLCO) | Canada | $5.601B | 25.63 |
| Organon (OGN) | United States | $4.041B | 4.12 |
| Sotera Health (SHC) | United States | $3.829B | 20.49 |
| BrightSpring Health Services (BTSG) | United States | $3.552B | 75.56 |
| Surgery Partners (SGRY) | United States | $3.263B | 37.20 |
| Concentras Parent (CON) | United States | $2.981B | 0.00 |
| GeneDx Holdings (WGS) | United States | $2.791B | 338.60 |
| Alignment Healthcare (ALHC) | United States | $2.755B | 0.00 |
| Teladoc Health (TDOC) | United States | $2.185B | 0.00 |
| Ardent Health Partners (ARDT) | United States | $2.118B | 0.00 |
| Progyny (PGNY) | United States | $2.033B | 41.17 |
| PACS (PACS) | United States | $2.010B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.852B | 48.60 |
| Premier (PINC) | United States | $1.726B | 11.05 |
| Agilon Health (AGL) | United States | $1.492B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.480B | 12.40 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.409B | 0.00 |
| CareDx (CDNA) | United States | $1.254B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.984B | 7.81 |
| Establishment Labs Holdings (ESTA) | $0.981B | 0.00 | |
| Embecta (EMBC) | United States | $0.838B | 5.74 |
| Auna S.A (AUNA) | Luxembourg | $0.611B | 0.00 |
| DocGo (DCGO) | United States | $0.513B | 19.35 |
| SBC Medicals (SBC) | United States | $0.483B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.480B | 0.00 |
| MultiPlan (MPLN) | United States | $0.477B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.453B | 0.00 |
| Enhabit (EHAB) | United States | $0.424B | 36.70 |
| Nutex Health (NUTX) | United States | $0.335B | 0.00 |
| LifeMD (LFMD) | United States | $0.326B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.311B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.294B | 7.71 |
| Beauty Health (SKIN) | United States | $0.199B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.183B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.144B | 0.00 |
| Biodesix (BDSX) | United States | $0.134B | 0.00 |
| So-Young (SY) | China | $0.114B | 19.40 |
| IceCure Medical (ICCM) | Israel | $0.083B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.081B | 0.00 |
| ModivCare (MODV) | United States | $0.079B | 4.29 |
| Oncology Institute (TOI) | United States | $0.068B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 1.62 |
| Singular Genomics Systems (OMIC) | United States | $0.051B | 0.00 |
| OncoCyte (OCX) | United States | $0.047B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.035B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.023B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.019B | 0.00 |
| KindlyMD (KDLY) | United States | $0.018B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.011B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.008B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.006B | 0.00 | |
| XWELL (XWEL) | United States | $0.006B | 0.00 |
| Aclarion (ACON) | United States | $0.003B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |